Commercial Readiness for Acquired Hypothalamic Obesity September 24, 2025 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of our products and product candidates, including setmel ...

Core Insights - Palatin Technologies, Inc. announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, demonstrating effectiveness in rodent models of obesity [1][2] - The company plans to initiate a Phase 1 clinical trial for PL7737 in late 2025, with data expected in the first half of 2026 [2][5] Group 1: Preclinical Study Results - The preclinical study evaluated the weight loss effects of PL7737 in a diet-induced obese rat model, showing statistically significant weight loss after 4 days of treatment [2] - PL7737 monotherapy resulted in a 5% weight loss at the middle dose and 10% at the high dose, while the combination with tirzepatide led to an 11% and 15% weight loss, respectively [6] Group 2: Mechanism and Pipeline - MC4R agonists, like PL7737, offer a unique mechanism of action for obesity treatment, differing from incretin-based therapies [2] - Palatin is developing a pipeline of novel MC4R agonists, including both oral and long-acting peptide candidates, targeting general obesity and rare forms of the disease [2][9] Group 3: Regulatory and Market Potential - The FDA granted orphan drug designation to PL7737 for treating leptin receptor deficiency-related obesity, a rare genetic disorder [2] - There are currently no approved pharmacologic treatments specifically indicated for hypothalamic obesity, highlighting a significant unmet medical need [7]